Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Akums Drugs Secures 20-Year Patent for Advanced Gastro-Resistant Dual-Release PPI Tablet
With this milestone, Akums strengthens its position in the acid-suppression market and sets the stage for further innovation in gastro-intestinal therapeutics.
- By Newsdesk
- New Delhi
- Nov 04, 2025
Indian pharmaceutical firm Akums Drugs and Pharmaceuticals Ltd has been granted a 20-year patent for its innovative “Dual Release Gastro-Resistant Composition”, beginning from 19 November 2022 under the provisions of the Patents Act, 1970.
The patented formulation is designed as a next-generation proton pump inhibitor (PPI) tablet aimed at patients with moderate to severe or treatment-resistant Gastroesophageal reflux disease (GERD). As one of the world’s most common digestive disorders, GERD affects an estimated 14 % of the global population — which in India is around a pooled prevalence of 15.6 %.
Conventional PPI therapies often fall short due to short duration of action or failure to control nocturnal acid breakthrough. To address this gap, Akums’ dual-release tablet employs a tablet-in-tablet technology that delivers 50 % of the dose in the duodenum and the remaining 50 % in the ileum, thereby extending the drug’s absorption window and therapeutic duration. This once-daily formulation also claims enhanced stability, more uniform drug release, and improved patient compliance and quality of life.
In addition to patent grant, the product has received approval from India’s central drug regulator, reinforcing Akums’ commitment to delivering patient-friendly, clinically-governed treatments for chronic acid-related disorders.
With this milestone, Akums strengthens its position in the acid-suppression market and sets the stage for further innovation in gastro-intestinal therapeutics.